PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3196590

An electromagnetic pneumatic blood pump driver.

R L Whalen·R N Briskman
View original source ↗Export metadata ↓

Abstract

An electromagnetic pneumatic pump driver has been developed with the goals of enhanced mechanical reliability and simplicity of operation. The new driver eliminates failure prone components such as solenoid valves or pressure regulators common to conventional pneumatic drive systems, has only a single moving part, and provides for closed-loop operation in which stroke volume and dP/dT are controlled on each beat in real time. Power is provided by a high force (178 N) electromagnetic linear actuator. This assembly uses a high energy density neodymium-iron-boron permanent magnet, low loss vanadium alloy pole pieces, and an energized moving coil. The nominal stroke length of the actuator is 1.7 cm. During operation, the moving coil always remains within a fixed annular air gap, resulting in a measured force output versus applied power linearity of better than 92% over its stroke range. The coil is directly attached to the free end of a 10 cm diameter, 21 convolution, welded titanium metal bellows that forms the gas containing element of the system. The comparatively low pressure gradients across the bellows in this application result in a predicted life for the bellows in excess of 10(9) cycles. Bellows position and internal pressure are monitored continuously to control the pneumatic output. The linear actuator total excursion and velocity are adjusted on each beat using a closed-loop servo system. This results in a pump driver with no operator required adjustment of drive pressure. Instead, there are user selected settings of stroke volume, operating mode, and fill sensitivity.(ABSTRACT TRUNCATED AT 250 WORDS)

Explore related subjects

Assisted CirculationElectric Power SuppliesElectromagnetic PhenomenaEquipment DesignHeart-Assist DevicesHumansJournal ArticleResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R L Whalen, R N Briskman. An electromagnetic pneumatic blood pump driver.. https://pubmed.ncbi.nlm.nih.gov/3196590/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Percutaneous endocardial and epicardial ablation of hypotensive ventricular tachycardia with percutaneous left ventricular assist in the electrophysiology laboratory.

Ventricular tachycardia (VT) in the setting of structural heart disease is challenging to treat with percutaneous catheter ablation due to the presence of complex substrate, multiple morphologies, hemodynamic instability, and epicardial circuits. When substrate-based approaches fail, however, it may be impossible to map and ablate hemodynamically unstable arrhythmias. We describe a novel approach to endocardial and epicardial mapping and ablation of hypotensive VT using a percutaneous left ventricular assist device in the electrophysiology laboratory, permitting near-surgical access to cardiac structures.

Assisted Circulation↗
PubMed2006

IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support.

Commercial immunoassays frequently detect anti-PF4/heparin antibodies during mechanical circulatory support (MCS), but only a small minority of patients develops heparin-induced thrombocytopenia (HIT). Whereas platelet functional tests can distinguish between platelet-activating and non-platelet-activating antibodies, commercial PF4-dependent immunoassays do not. Between 2003 and 2004, 113 patients were placed on MCS. Blood samples were obtained on postimplant day 5-7 for analyses by antibody assays and the functional heparin-induced platelet activation (HIPA) assay. Three distinct groups of patient sera were identified: platelet-activating anti-PF4/heparin antibodies (n = 10), non-platelet-activating anti-PF4/heparin antibodies (n = 53), and anti-PF4/heparin antibody negative (n = 50). Patients with platelet-activating antibodies had the highest risk for thromboembolic events (P < 0.005), whereas those with non-platelet-activating antibodies did not differ from antibody negative patients (P = 0.369). The enzyme-immunoassay and column agglutination assays, which cover all immunoglobulin classes, demonstrated adequate sensitivity and negative predictive value; yet, both lacked specificity with respect to the platelet-activating antibodies. If all antibody positive patients were further classified by an IgG-specific anti-PF4/heparin enzyme-immuno assay, specificity for platelet-activating antibodies increased. Whereas IgG-specific optical density (OD) values below 1.0 were likely for non-platelet-activating anti-PF4/heparin antibodies, higher values were progressively predictive for pathogenic platelet activation. The probability of the development of clinical HIT also increased steeply. In conclusion, platelet-activating anti-PF4/heparin antibodies are relatively common (about 9%) in patients on MCS and are associated with significantly higher thrombotic event rates. Low IgG-specific OD values (< 1.0) in the enzyme-immunoassay indicate low likelihood for the presence of platelet-activating antibodies. These results justify further validation so that anticoagulation during MCS becomes safer and adequate.

Assisted Circulation↗